BiotechTube

Eribulin + Lenvatinib

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer, Solid Tumor

Trial Timeline

May 1, 2016 → Jan 12, 2023

NCT ID
NCT02640508

About Eribulin + Lenvatinib

Eribulin + Lenvatinib is a phase 2 stage product being developed by Eisai for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02640508. Target conditions include Cancer, Solid Tumor.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02640508Phase 2Completed

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
XL820ExelixisPhase 1
26
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35